DK1385577T3 - Anvendelse af NK-1-receptorantagonister mod godartet prostatahyperplasi - Google Patents

Anvendelse af NK-1-receptorantagonister mod godartet prostatahyperplasi

Info

Publication number
DK1385577T3
DK1385577T3 DK02719751T DK02719751T DK1385577T3 DK 1385577 T3 DK1385577 T3 DK 1385577T3 DK 02719751 T DK02719751 T DK 02719751T DK 02719751 T DK02719751 T DK 02719751T DK 1385577 T3 DK1385577 T3 DK 1385577T3
Authority
DK
Denmark
Prior art keywords
receptor antagonists
benign prostatic
prostatic hyperplasia
antagonists against
against benign
Prior art date
Application number
DK02719751T
Other languages
Danish (da)
English (en)
Inventor
Susanne Buser
Anthony P D W Ford
Barbara Lenz
Andrew John Sleight
Pierre Vankan
Torsten Hoffmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1385577T3 publication Critical patent/DK1385577T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK02719751T 2001-04-23 2002-02-02 Anvendelse af NK-1-receptorantagonister mod godartet prostatahyperplasi DK1385577T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01109853 2001-04-23

Publications (1)

Publication Number Publication Date
DK1385577T3 true DK1385577T3 (da) 2006-08-21

Family

ID=8177209

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02719751T DK1385577T3 (da) 2001-04-23 2002-02-02 Anvendelse af NK-1-receptorantagonister mod godartet prostatahyperplasi

Country Status (17)

Country Link
US (1) US20030004157A1 (enExample)
EP (1) EP1385577B1 (enExample)
JP (1) JP4146730B2 (enExample)
KR (1) KR100599134B1 (enExample)
CN (1) CN100398106C (enExample)
AR (1) AR035935A1 (enExample)
AT (1) ATE323531T1 (enExample)
AU (1) AU2002250876B2 (enExample)
BR (1) BR0209151A (enExample)
CA (1) CA2444395C (enExample)
DE (1) DE60210760T2 (enExample)
DK (1) DK1385577T3 (enExample)
ES (1) ES2261657T3 (enExample)
MX (1) MXPA03009720A (enExample)
PT (1) PT1385577E (enExample)
WO (1) WO2002085458A2 (enExample)
ZA (1) ZA200308110B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002259147A1 (en) * 2001-05-08 2002-11-18 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
US6849624B2 (en) 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
PL378404A1 (pl) * 2003-01-31 2006-04-03 F. Hoffmann-La Roche Ag Nowa odmiana krystaliczna 2-(3,5-bis-trifluorometylofenylo)-N-[6-(1,1-diokso-1<$Elambda>6 -tiomorfolin-4-ylo)-4-(4-fluoro-2-metylofenylo)pirydyn-3-ylo]-N-metyloizobutyroamidu
HRP20070471T3 (hr) * 2003-07-03 2007-11-30 F. Hoffmann - La Roche Ag Dvojni nk1/nk3 antagonisti za liječenje shizofrenije
ES2246687B2 (es) * 2004-02-11 2006-11-16 Miguel Muñoz Saez Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
MX2007000198A (es) 2004-07-06 2007-03-15 Hoffmann La Roche Proceso para la preparacion de derivados de carboxamida-piridina utilizados como intermediarios en la sintesis de antagonistas del receptor nk-1.
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
NZ560232A (en) 2005-02-25 2010-11-26 Hoffmann La Roche Tablets with improved drug substance dispersibility
EP2774925B1 (en) 2005-11-08 2016-12-28 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of ATP-binding cassette transporters
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
JP2010516731A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド 2−メトキシ−5−(5−トリフルオロメチル−テトラゾール−1−イル)−ベンジル]−(2s−フェニル−ピペリジン−3s−イル)−アミンを含む医薬組成物
WO2008141119A2 (en) 2007-05-09 2008-11-20 Vertex Pharmaceuticals Incorporated Modulators of cftr
PL2231606T3 (pl) 2007-12-07 2013-07-31 Vertex Pharma Sposoby wytwarzania kwasów cykloalkilokarboksyamidopirydynobenzoesowych
HUE031913T2 (en) 2007-12-07 2017-08-28 Vertex Pharma Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
JP5523352B2 (ja) 2008-02-28 2014-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド Cftr修飾因子としてのへテロアリール誘導体
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
CA2755697A1 (en) 2009-03-17 2010-09-23 Daiichi Sankyo Company, Limited Amide derivative
WO2010119347A1 (en) * 2009-04-14 2010-10-21 Helsinn Healthcare S.A. Netupitant for use in treating bladder dysfunction
WO2011053522A1 (en) * 2009-10-29 2011-05-05 Merck Sharp & Dohme Corp. Tertiary amide orexin receptor antagonists
RS62767B1 (sr) 2010-04-07 2022-01-31 Vertex Pharma Farmaceutski sastavi 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiriodin-2-il)benzojeve kiseline i njihova primena
MX355183B (es) 2012-01-25 2018-04-09 Vertex Pharma Formulaciones de acido 3- (6- (1- (2.2- difluorobenzo [d] [1,3] dioxol-5-il) ciclopropancarboxamido) -3- metilpiridin-2-il) benzoico.
BR112016009811A2 (pt) 2013-11-08 2017-12-05 Kissei Pharmaceutical derivado de carboximetil piperidina
HRP20210516T2 (hr) 2013-11-12 2021-10-01 Vertex Pharmaceuticals Incorporated Postupak proizvodnje farmaceutskih pripravaka za liječenje bolesti koje su posredovane putem cftr
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
KR102576006B1 (ko) 2014-11-18 2023-09-06 버텍스 파마슈티칼스 인코포레이티드 고처리량 시험 고성능 액체 크로마토그래피의 수행 방법
MX2020008138A (es) * 2018-02-02 2020-10-19 Eustralis Pharmaceuticals Ltd Trading As Pressura Neuro Formulaciones parentales y usos de estas.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6175013B1 (en) * 1994-06-10 2001-01-16 Eli Lilly And Company Imidazolinyl tachykinin receptor antagonists
FR2729951B1 (fr) * 1995-01-30 1997-04-18 Sanofi Sa Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
CA2298702A1 (en) * 1997-08-06 1999-02-18 Eli Lilly And Company 2-acylaminopropanamines as tachykinin receptor antagonists
KR20010022581A (ko) * 1997-08-06 2001-03-26 피터 지. 스트링거 타키키닌 수용체 길항제인 2-아실아미노프로판아민
JPH11322748A (ja) * 1998-03-19 1999-11-24 Takeda Chem Ind Ltd 複素環化合物、その製造法および用途
DK1394150T3 (da) * 1999-02-24 2011-03-21 Hoffmann La Roche 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
AU3735000A (en) * 1999-05-05 2000-11-21 Warner-Lambert Company Modulation of substance p by gaba analogs and methods relating thereto
CN1178917C (zh) * 2000-07-14 2004-12-08 弗·哈夫曼-拉罗切有限公司 作为nk1受体拮抗剂前药的4-苯基-吡啶衍生物的n-氧化物
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides

Also Published As

Publication number Publication date
AR035935A1 (es) 2004-07-28
ES2261657T3 (es) 2006-11-16
CN1503684A (zh) 2004-06-09
CN100398106C (zh) 2008-07-02
EP1385577A2 (en) 2004-02-04
DE60210760T2 (de) 2006-11-23
KR100599134B1 (ko) 2006-07-12
EP1385577B1 (en) 2006-04-19
ZA200308110B (en) 2005-03-30
AU2002250876B2 (en) 2005-03-03
CA2444395C (en) 2010-12-21
WO2002085458A3 (en) 2003-10-30
JP2004529931A (ja) 2004-09-30
MXPA03009720A (es) 2004-01-29
DE60210760D1 (de) 2006-05-24
WO2002085458A2 (en) 2002-10-31
CA2444395A1 (en) 2002-10-31
ATE323531T1 (de) 2006-05-15
JP4146730B2 (ja) 2008-09-10
KR20040007503A (ko) 2004-01-24
BR0209151A (pt) 2004-07-13
PT1385577E (pt) 2006-08-31
US20030004157A1 (en) 2003-01-02

Similar Documents

Publication Publication Date Title
MXPA03009720A (es) USO DE ANTAGONISTAS DEL RECEPTOR DE NK-1 PARA TRATAMIENTO O PREVENCIoN DE HIPERPLASIA PROSTATICA BENIGNA.
DK1345920T3 (da) Hidtil ukendte sulfamider og anvendelse deraf som endothelinreceptorantagonister
PT1208104E (pt) Inibidores triciclicos de polimerases de poli(adp-ribose)
DK1339678T3 (da) Selektive agonister til EP4-receptor til behandling af osteoporose
NO20030471D0 (no) Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor
DK1307181T3 (da) Hidtil ukendte sammensætninger af minoxidil
DE60120419D1 (de) 4-phenyl-pyridin-derivate verwendbar als neurokinin-1 rezeptor antagonisten
DK1438306T3 (da) Derivater af UK-2A
DK1505998T3 (da) Forbedret anvendelse af hop-syrer som antimikrobielle midler
LV12770B (lv) Poli(adp-ribozo) polimerazu tricikliskie inhibitori
DK1157005T3 (da) 3-phenylpyridinderivater og anvendelsen deraf som NK-1-receptorantagonister
DK1458447T3 (da) Kombination af cytokrom-p450-beroende proteasinhibitorer
IL169685A0 (en) Treatment of benign prostatic hyperplasia using energolytic agents
FI20001512L (fi) Salaamattoman käyttäjäliikenteen kontrollointi
EP1368136A4 (en) PROCESS FOR CLEANING MICROELECTRONIC STRUCTURES
DK1274427T3 (da) Formulering af substituerede benzimidazoler
DE60222693D1 (de) Nk1-antagonisten
NO20041968L (no) Anvendelse av cystationin
DK1399016T3 (da) Fremgangsmåde til generering af diversitet
DK1276721T3 (da) Methylering af indolforbindelser under anvendelse af dimethylcarbonat
DK1296961T3 (da) 1,4-diazepan-2,5-dionderivater og anvendelse deraf som NK-1-receptorantagonister
IS2725B (is) Inndælingarlausn sem samanstendur af LHRH mótlyfi
DK1408964T3 (da) Hidtil ukendt anvendelse af 2-5-(4-fluorphenyl)-3-pyridylmethylaminomethyl-chroman og fysiologisk acceptable salte deraf
ID30023A (id) Kombinasi senyawa aktif fungisida
NO20023785D0 (no) Vanndispergerbar formulering av paroxetin